TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06472791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Centella Asiatica
Description: Centella Asiatica is a perennial, herbaceous plant that is sold as a dietary supplement in the United States under the name Gotu Kola. It has been used for centuries in Ayurvedic and Chinese medicine. Evidence suggests it may help with resilience to aging and cognitive decline. The product for this study will be produced by Arjuna Natural.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The comparator will contain microcystalline cellulose in matched capsules. The comparator product for this study will be produced by Arjuna Natural.
Study: NCT06169527

Intervention type: DRUG
Intervention: Dupilumab
Description: Dupilumab cohort
Study: NCT05668507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACHOUT Virtual Mental Health Support
Description: REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~1. One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~2. Group support delivered via a 24/7 chat room~3. Face to face support delivered via virtual happy hours
Study: NCT04409418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extended dwell catheters
Description: EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended dwell catheters
Description: EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
Study: NCT06456684

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluoro[18F]promethazine
Description: It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluoro[18F]promethazine
Description: It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease
Study: NCT05318625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gynaecological laparoscopic surgery (Sirius System)
Description: The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay.
Study: NCT05379023

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face-to-face evaluation (FF)
Description: The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
Study: NCT05658640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral/ Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal chemotherapy
Description: IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
Study: NCT05379023

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face-to-face evaluation (FF)
Description: The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TeleNP evaluation
Description: The intervention is the assessment modality. The intervention condition is TeleNP evaluation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TeleNP evaluation
Description: The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
Study: NCT05716607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OD dual-release Hydrocortisone
Description: Treatment with once-daily dual-release hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TID Hydrocortisone
Description: Treatment with thrice-daily conventional immediate-release hydrocortisone
Study: NCT06358508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire 3 Coronary Dilatation Catheter
Description: To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.
Study: NCT05377216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Left sided percutaneous stellate ganglion block
Study: NCT04943068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
Study: NCT06521736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAC-BCI device
Description: Participants without speech and severe movement disorders will be trained on the augmentative and alternative communication, brain-computer interface (AAC-BCI) system, using it for at least 10 hours per week in their homes for communication and other control functions. Participants will have daily support for using the AAC-BCI from trained caregivers along with intervention support from consultants and speech language pathologists.
Study: NCT05162794

Intervention type: OTHER
Group type: OTHER
Intervention: Laparoscopy with excision
Description: Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Laparoscopy without excision
Description: Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Medical treatment-as-usual
Description: Patients continue their hormonal and analgesic treatment-as-usual.

Intervention type: OTHER
Group type: OTHER
Intervention: Medical treatment-as-usual
Description: Patients continue their hormonal and analgesic treatment-as-usual.

Intervention type: OTHER
Group type: OTHER
Intervention: Medical treatment-as-usual
Description: Patients continue their hormonal and analgesic treatment-as-usual.
Study: NCT05848843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Given by PO
Study: NCT05926661

Intervention type: OTHER
Group type: OTHER
Intervention: NCC Support Toolkit
Description: Pre-discharge intervention-~* Set expectations for parents/caregivers to spend time bedside and attend rounds~* iPad for the families to use the Nemours App, download education materials and Facetime communication with medical personnel.~* Download Nemours App and teach them how to use it~* Education materials- to ease the use of medications, Oxygen and feeding~* Assistance with transportation, child care, parental work schedule for discharge teaching~Post Discharge intervention (Day 1-2):~• Video/Facetime call with the family to check equipment, home environment and answer questions about medications and formula~Post discharge intervention (Day 3-7):~• Phone call to the family to ensure transportation for their first follow-up appointment, answer questions about medications, Oxygen and feeding.
Study: NCT05927961

Intervention type: DIAGNOSTIC_TEST
Intervention: histopathology
Description: There is a clear boundary between adrenal adenoma and surrounding normal tissue. There is no clear boundary between adrenal hyperplasia and surrounding normal tissues.

Intervention type: DIAGNOSTIC_TEST
Intervention: histopathology
Description: There is a clear boundary between adrenal adenoma and surrounding normal tissue. There is no clear boundary between adrenal hyperplasia and surrounding normal tissues.
Study: NCT05159882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-1442 and Dapagliflozin placebo
Description: THR-1442 tablets 20mg and Dapagliflozin tablets placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg and THR1442 placebo
Description: Dapagliflozin tablets 10mg and THR-1442 tablets placebo
Study: NCT06325397

Intervention type: OTHER
Intervention: High Intraocular Pressure (IOP)
Description: Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with Intraocular Pressure (IOP) ≤ 24 millimeters of mercury (mmHg) (low IOP) in one eye and with IOP ≥ 65 millimeters of mercury (mmHg) (high IOP) in the other eye.

Intervention type: OTHER
Intervention: Low Intraocular Pressure (IOP)
Description: Low Intraocular Pressure (IOP) Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 24 millimeters of mercury (mmHg) (low IOP) in one eye and with IOP ≥ 65 millimeters of mercury (mmHg) (high IOP) in the other eye
Study: NCT05848843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Given by PO
Study: NCT05785000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise programme as an add-on
Description: Consists of an individually tailored bike exercise program guided by symptoms, pulse rate and patient specific judgement of exertion monitored also by BORG RPE and VAS and progressively increasing time and level of resistance below symptom provocation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control patients receiving usual care
Description: No exercise intervention
Study: NCT05318560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: for MPS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone
Description: for MPS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: for MPS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: for MPS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: for MPS
Study: NCT05650294

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PL+ omega 3 fatty acids
Description: PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PL+ omega 3 fatty acids
Description: PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FO EE fatty acids
Description: A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FO EE fatty acids
Description: A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
Study: NCT05508516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shugan Dingtong decoction
Description: Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride
Description: Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
Study: NCT06283082

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lithiasis assessment
Description: Measurement of oxaluria and glycolaturia on 24 h urine collection, identification of lithiasis disease (biological and ultrasound) and search for lithiasis risk factors.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lithiasis assessment
Description: Measurement of oxaluria and glycolaturia on 24 h urine collection, identification of lithiasis disease (biological and ultrasound) and search for lithiasis risk factors.
Study: NCT06085560

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Message
Description: Usual care is provided by the FQHC for the screening option chosen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Intention Intervention: Standard Message
Description: Implementation Intention Intervention module includes standard messaging in addition to the usual care provided by the FQHC for the screening option chosen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intention Intervention: Culturally-Targeted Message
Description: Implementation Intention Intervention module includes culturally-targeted framing of health information messages in addition to the usual care provided by the FQHC for the screening option chosen.
Study: NCT06176612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total hip arthroplasty
Description: Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent hip replacement
Study: NCT05962840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Telitacicept
Description: Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
Study: NCT06080217

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: study group
Description: The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: study group
Description: The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo (sham control)
Description: The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, but without any energy transferred through the probe,
Study: NCT05170542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+S-1
Description: Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
Study: NCT05685680

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision in rectal carcinoma
Description: total mesorectal excision laparoscopic versus open technique in management of rectal carcinoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision in rectal carcinoma
Description: total mesorectal excision laparoscopic versus open technique in management of rectal carcinoma
Study: NCT05099887

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Procenta conformable barrier
Description: Wound care dressing biologic allograft
Study: NCT05463211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trexo Plus Pediatric Exoskeleton
Description: Wearable pediatric robotic walker for the lower extremities
Study: NCT05250752

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
Study: NCT05013619

Intervention type: OTHER
Intervention: Circumstances of pain
Description: It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.

Intervention type: OTHER
Intervention: Pain Questionnaire
Description: Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain.

Intervention type: OTHER
Intervention: Pain Questionnaire
Description: Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain.

Intervention type: OTHER
Intervention: Gross Motor Functional Classification System
Description: Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent

Intervention type: OTHER
Intervention: The subtypes of Cerebral palsy
Description: The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
Study: NCT04748783

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peroxyl
Description: Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peroxyl
Description: Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periogard
Description: Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periogard
Description: Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Total Zero
Description: Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
Study: NCT05682807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 5-10 mg/kg/day IV maintenance dose given after 24 h for 2 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months.